ADHD and Lemborexant
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Based on the textbook sources, here is a focused synthesis of ADHD, sleep, and lemborexant:
ADHD and Sleep
ADHD is strongly associated with sleep disturbances. Key findings from the literature:
- Sleep problems occur in up to half of children with ADHD, and are reported at up to fivefold higher rates than in healthy controls — Kaplan & Sadock's Comprehensive Textbook of Psychiatry
- Common sleep complaints include difficulty settling to sleep, greater variation in sleep-onset time, bedtime struggles, and longer total sleep duration
- Children with ADHD have a higher prevalence of sleep-disordered breathing (SDB), periodic limb movement disorder (PLMD), and habitual snoring (3x more common than controls)
- Circadian rhythm abnormalities are frequent, with delayed dim-light melatonin onset contributing to sleep-onset insomnia
- Crucially, sleep restriction in otherwise healthy children can itself produce ADHD-like symptoms — inattention, hyperactivity, impulsivity, and poor cognitive performance — creating a bidirectional relationship
Managing Sleep in ADHD
When insomnia is driven by stimulant medication, options include lowering the dose, switching to a shorter-acting preparation, adding a small booster dose (if rebound is the cause), or switching to atomoxetine. Adjunctive pharmacotherapy includes melatonin, clonidine, diphenhydramine, trazodone, and mirtazapine. — Kaplan & Sadock's
Lemborexant: Mechanism and Profile
Lemborexant (brand: Dayvigo) is a dual orexin receptor antagonist (DORA), FDA-approved in 2019 for insomnia.
Mechanism
Orexins (hypocretins) are neuropeptides produced by lateral hypothalamic neurons. They promote and stabilize wakefulness by activating histamine, acetylcholine, norepinephrine, dopamine, and serotonin release. During sleep, orexin neurons are quiescent; loss of these neurons causes narcolepsy.
Lemborexant blocks both orexin 1 (OX1R) and orexin 2 (OX2R) receptors, with higher affinity for OX2R than OX1R (unlike suvorexant, which has comparable affinity for both). It exhibits faster association and dissociation kinetics at OX2R, which may translate to faster reversibility in the morning as endogenous orexin levels rise. — Stahl's Essential Psychopharmacology
Key Pharmacology
| Feature | Detail |
|---|---|
| Dose | 2.5–10 mg at bedtime |
| Half-life | 17–19 hours |
| Indication | Sleep-onset and sleep-maintenance insomnia |
| Schedule | IV controlled substance |
| Most common adverse effect | Somnolence (especially at higher doses) |
Advantages Over Benzodiazepines / Z-drugs
Lemborexant and DORAs as a class lack: dependence, withdrawal, rebound insomnia, anterograde amnesia, unsteady gait/falls, confusion, or respiratory depression. — Goodman & Gilman's; Stahl's
As endogenous orexin builds in the morning, it competes with lemborexant for receptor binding. At night the drug-to-orexin ratio is high (promotes sleep); by morning, rising orexin displaces the drug and the patient awakens naturally.
Lemborexant in ADHD Context
There is no direct textbook evidence of lemborexant being studied or approved specifically for ADHD-associated insomnia. However, the pharmacological rationale is relevant:
- ADHD stimulant medications (methylphenidate, amphetamine) work partly by activating dopamine pathways that downstream trigger orexin release to stabilize wakefulness — this is the mechanism for their pro-wakefulness effects. — Stahl's
- A DORA like lemborexant could theoretically address stimulant-driven insomnia by blocking orexin-mediated wake-promotion without the amnesia and dependence risks of benzodiazepines or Z-drugs.
- Current evidence-based adjunctive choices for ADHD sleep remain melatonin and clonidine; lemborexant would be considered off-label in this context.
Sources: Stahl's Essential Psychopharmacology; Goodman & Gilman's Pharmacological Basis of Therapeutics; Katzung's Basic and Clinical Pharmacology; Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Lippincott Illustrated Reviews: Pharmacology
Management of gastrocolic reflex
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Here is a comprehensive overview of the gastrocolic reflex and its management:
Gastrocolic Reflex — Physiology
Distension of the stomach by food increases colonic motility and the frequency of mass movements in the large intestine. This is a long-arc reflex with:
- Afferent limb: gastric distension, mediated via the parasympathetic nervous system
- Efferent limb: increased colonic motility, mediated by the hormones CCK and gastrin
A caloric load of ~300 kcal is required to generate a full colonic response; fat is the most potent stimulus (600 kcal fat produces a dramatic contractile response, while equicaloric protein or carbohydrate has minimal effect). Non-nutrient gastric distension (e.g., water or balloon) can also stimulate rectosigmoid motility. 5-HT3 receptors on vagal afferents appear to be involved — granisetron markedly attenuates the response. — Sleisenger & Fordtran's GI and Liver Disease; Costanzo Physiology; Ganong's Review
In adults, habit and cultural factors modulate the reflex heavily; in infants and children it is more pronounced and uninhibited.
Management Contexts
The gastrocolic reflex is relevant in three main clinical scenarios:
1. Harnessing the Reflex — Bowel Training (Constipation / Fecal Incontinence)
Goal: achieve predictable, scheduled defecation by exploiting the postprandial colonic response.
Strategy: Attempt defecation immediately after meals (especially breakfast), when the reflex is strongest. This is particularly effective in the morning to provide freedom from fecal incontinence throughout the day.
Adjuncts to enhance this approach:
- Suppositories or enemas (glycerin, bisacodyl) timed to coincide with the postprandial window
- Increased dietary fiber (20–35 g/day) and adequate fluid intake
- Physical activity (Kegel exercises, general exercise)
- Regular toileting schedules — particularly effective in institutionalized elderly patients with overflow incontinence from fecal impaction
- For spinal cord injury patients with a diminished gastrocolic reflex: stool softeners, laxatives, digital anal stimulation (relaxes puborectalis), manual evacuation, enemas, and anterior sacral root stimulators; colostomy may be considered for quality-of-life improvement — Yamada's Textbook of Gastroenterology; Berek & Novak's Gynecology
2. Attenuating an Exaggerated Reflex — IBS-D and Postprandial Urgency
In IBS (diarrhea-predominant), the gastrocolic reflex is enhanced, contributing to increased high-amplitude propagated contractions (HAPCs) and rectal hypersensitivity following meals.
Management:
- Dietary modification: Low-fat meals reduce the colonic motor stimulus (fat is the most potent activator)
- Low-FODMAP diet: reduces fermentable substrate and gas-driven colonic stimulation
- 5-HT3 antagonists (e.g., alosetron, ondansetron): attenuate the 5-HT3-mediated vagal component of the gastrocolic response
- Antispasmodics (e.g., hyoscine/dicyclomine): reduce colonic smooth muscle reactivity to the reflex
- Loperamide: slows colonic transit and reduces urgency, especially useful for predictable postprandial diarrhea (can be taken prophylactically before meals)
- Tricyclic antidepressants (TCAs) at low doses: reduce visceral hypersensitivity
- Psychological/behavioral approaches: biofeedback, relaxation techniques, and behavioral modification are useful adjuncts — Sleisenger & Fordtran's; Berek & Novak's
3. Impaired Gastrocolic Reflex — Neurological Conditions
The reflex is diminished in:
- Diabetes mellitus (autonomic neuropathy) — contributes to slow colonic transit and constipation
- Spinal cord injury (SCI) — elimination of supraspinal modulation
- Multiple sclerosis
Management in these settings focuses on substituting for the absent reflex signal:
- Stimulant laxatives (bisacodyl, senna) to directly trigger HAPCs via mucosal nerve activation
- Osmotic laxatives (PEG, lactulose) for softening and transit promotion
- Cholinergic agents (prucalopride as a 5-HT4 agonist) to stimulate enteric nervous system propulsion
- Digital rectal stimulation and suppositories to initiate defecation
- Loperamide or codeine phosphate judiciously in MS-associated diarrhea — Yamada's; Sleisenger & Fordtran's
Summary Table
| Clinical Context | Problem | Key Management |
|---|---|---|
| Constipation / fecal incontinence | Reflex underutilized | Post-meal toileting, suppositories, fiber, fluids |
| IBS-D / postprandial urgency | Reflex exaggerated | Low-fat diet, loperamide, 5-HT3 antagonists, antispasmodics |
| SCI / diabetic autonomic neuropathy | Reflex diminished | Stimulant laxatives, digital stimulation, scheduled bowel care |
| Multiple sclerosis | Variable | Fiber, fluids, loperamide or codeine (diarrhea), bowel training |
Sources: Sleisenger & Fordtran's Gastrointestinal and Liver Disease; Yamada's Textbook of Gastroenterology; Costanzo Physiology; Ganong's Review of Medical Physiology; Berek & Novak's Gynecology
This is a shared conversation. Sign in to Orris to start your own chat.